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ABSTRACT 
PRH/Hhex (Proline Rich Homeodomain protein) is a transcription factor that controls cell 
proliferation and cell differentiation in a variety of tissues. Aberrant subcellular localisation 
of PRH is associated with breast cancer and thyroid cancer. Furthermore, in blast crisis 
chronic myeloid leukaemia, and a subset of acute myeloid leukaemias, PRH is aberrantly 
localised and its activity is down-regulated. Here we show that PRH is involved in the 
regulation of cell migration and cancer cell invasion.  We show for the first time that PRH is 
expressed in prostate cells and that a decrease in PRH protein levels increases the migration 
of normal prostate epithelial cells. We show that a decrease in PRH protein levels also 
increases the migration of normal breast epithelial cells. Conversely, PRH over-expression 
inhibits cell migration and cell invasion by PC3 and DU145 prostate cancer cells and MDA-
MB-231 breast cancer cells.  Previous work has shown that the TGF-β co-receptor Endoglin 
inhibits the migration of prostate and breast cancer cells.  Here we show that PRH can bind to 
the Endoglin promoter in immortalised prostate and breast cells. PRH over-expression in 
these cells results in increased Endoglin protein expression whereas PRH knockdown results 
in decreased Endoglin protein expression. Moreover, we demonstrate that Endoglin over-
expression abrogates the increased migration shown by PRH knockdown cells. Our data 
suggest that PRH controls the migration of multiple epithelial cell lineages in part at least 
through the direct transcriptional regulation of Endoglin.  We discuss these results in terms of 
the functions of PRH in normal cells and the mislocalisation of PRH seen in multiple cancer 
cell types. 
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INTRODUCTION   
The transcription factor PRH (Proline Rich Homeodomain/HHex) is essential for 
formation of the vertebrate body axis and the development of most organs including the 
heart, thyroid, pancreas, vasculature and haematopoietic compartment (1). PRH can activate 
or repress transcription of its target genes and it can also control gene expression at the post-
transcriptional level via a protein-protein interaction with eIF4E (2-5). In the mouse, 
retroviral expression of PRH leads to a T-cell leukaemia (6). Moreover, in human T-cell 
leukaemias associated with the aberrant expression of the LMO2 oncogene, elevated PRH 
expression is necessary for development of the disease (7, 8). However, more generally, it is 
the disruption of PRH activity that is associated with a variety of diseases states (9-12). 
Aberrant subcellular localisation of PRH with loss of nuclear PRH is associated with blast 
crisis chronic myeloid leukaemia (CML) and some subtypes of acute myeloid leukaemia 
(AML) (12). Furthermore in one human AML the only characterised genetic change is a 
fusion of the prh gene with the nucleoporin gene Nup98 and this is thought to decrease the 
activity of endogenous PRH (11). We have shown that in a CML cell line, BCR-ABL activity 
indirectly results in the down-regulation of PRH transcriptional repression activity and the 
derepression of several PRH target genes including Vegfa, Vegfr-1, and Vegfr-2 (13). The 
repression of these genes in CML K562 cells by PRH results in decreased VEGF autocrine 
signalling and decreased cell survival (13). Conversely, inactivation or down-regulation of 
PRH and the consequent de-repression of these genes results in increased cell survival. 
Significantly, decreased nuclear PRH protein is also associated with breast and thyroid 
tumours (9, 10).  
Endoglin is a TGF-β coreceptor that modulates TGF-β-dependent cellular responses 
(14, 15). Most studies on Endoglin have focused on its pro-angiogenic role in endothelial 
cells, its involvement in vascular remodelling and its role as a marker of the tumour 
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vasculature, but it also plays a direct role in tumourigenesis (16). Several studies have 
concluded that decreased Endoglin expression is associated with prostate cancer cell 
migration. For example, Endoglin expression was found to be lower in multiple cancer cell 
lines than in immortalised normal prostate cells and down-regulation of Endoglin expression 
was shown to increase prostate cancer cell migration and invasion (17). More recent data 
have shown that decreased Endoglin levels in prostate cancer cells result in increased 
metastasis and increased tumour size (18). The inhibition of prostate cell migration by 
Endoglin occurs through the activation of TGF-β co-receptor signalling and the consequent 
phosphorylation of Smad1, as well as through a Smad1-independent pathway (19, 20). 
Endoglin has also been shown to inhibit invasion and colony formation by esophageal 
epithelial cells (21) and to suppress cancer formation by skin epithelial cells (22).  Moreover, 
Endoglin inhibits the migration and invasion of breast tumour cells in vivo by modulating 
cytoskeletal remodeling rather than through TGF co-receptor modulation and low Endoglin 
expression correlates with poor prognosis in a panel of invasive breast tumours (23).  
Interestingly, PRH over-expression has been demonstrated to inhibit angiogenesis but 
to increase Endoglin mRNA and protein levels in human endothelial cells (24). However, it is 
not known whether Endoglin is a direct target for transcriptional regulation by PRH in these 
cells. It is also unknown whether the regulation of Endoglin by PRH occurs in other cell 
types and whether this could be important in tumourigenesis. Here we show that PRH 
regulates the migration of normal prostate and breast epithelial cells and that PRH over-
expression inhibits migration and invasion of prostate and breast tumour cells. Our findings 
suggest that in prostate cancer cells and breast cancer cells the regulation of Endoglin by 
PRH may be attenuated resulting in increased cell migration and cell invasion.   
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RESULTS 
PRH regulates cell migration 
 PNT2-C2 cells are a normal immortalised prostate epithelial cell line (25, 26). 
Western blotting reveals that PNT2-C2 cells express PRH (Fig.1A). To determine whether 
PRH plays an important role in these cells we performed a PRH knockdown experiment 
using specific shRNAs. PNT2-C2 cells were transfected with plasmids expressing PRH 
shRNA and selected in puromycin for 10 days. Western blotting confirms that PRH protein 
levels are significantly reduced in the PRH knockdown cells (PNT2-C2 KD cells) compared 
to cells expressing a control shRNA (Fig.1A and Fig.1B). To determine whether the PNT2-
C2 PRH KD cells exhibit increased cell motility we performed wound closure assays. 
Confluent layers of PNT2-C2 KD cells and control cells were wounded with a pipette tip and 
wound closure monitored over time using microscopy (Fig.1C). Interestingly, PNT2-C2 KD 
cells migrate into the wound significantly faster than control cells (Fig.1D). This experiment 
was performed in the presence of hydroxyurea to inhibit cell division and ensure that any 
effects of PRH knockdown on cell proliferation could not account for changes in cell 
migration. To investigate the effects of PRH on chemotaxis, we placed PNT2-C2 KD cells 
and control transfected cells in Boyden chambers and determined the number of cells that 
migrate towards high serum. After 4 hours significantly more PNT2-C2 KD cells than control 
cells migrate towards high serum (Fig.1E). Taken together these data show that PRH is 
expressed in prostate epithelial cells and that PRH knockdown increases cell migration.   
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PRH over-expression inhibits prostate cancer cell migration and invasion 
 To determine whether PRH also influences the migration of tumour cells we over-
expressed PRH in PNT2-C2 cells and two well-characterised prostate cancer cell lines, PC3 
cells and DU145 cells.  We transfected each cell line with a vector expressing GFP or with a 
GFP expression vector in combination with a PRH expression vector and we used GFP as a 
marker to follow the migration of transfected cells. In each case over-expression of PRH 
brings about a significant reduction in cell migration (Fig.2A).  We also examined the effects 
of PRH over-expression on the migration of DU145 cells using live cell imaging with time-
lapse video microscopy. DU145 cells transfected with GFP and PRH expression vectors 
migrated less distance than cells transfected with a GFP expression vector alone (Fig.S1A). 
They also showed a significant reduction in migration velocity and displacement (Fig.S1B 
and S1C, respectively). To determine whether the transcriptional activity of PRH is required 
to inhibit cell migration we expressed two PRH mutants in these cells. PRH N187A contains 
a mutation in the PRH homeodomain and is unable to bind DNA (4, 27). PRH F32E contains 
a mutation that blocks the binding of PRH to co-repressor proteins belonging to the TLE 
family (3, 27). Both of these mutated proteins show a significantly reduced ability to inhibit 
cell migration compared to wild type PRH (Fig.2B) although all three proteins are expressed 
at roughly equivalent levels (Fig.2C). This suggests that PRH inhibits cell migration via the 
transcriptional regulation of PRH-target genes.  
We next set out to determine whether PRH inhibits cancer cell invasion and 
extravasation. PNT2-C2 cells are normal immortalised cells that cannot invade a Matrigel 
layer, however, PC3 cells and DU145 cells expressing GFP alone are able to migrate through 
a Matrigel layer.  In contrast tumour cells expressing both GFP and PRH show a significant 
reduction in invasion (Fig.2D). Furthermore, in extravasation assays, PC3 cells expressing 
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PRH show a significant reduction in their ability to traverse a layer of endothelial cells placed 
over Matrigel (Fig.2E).  
 
PRH directly activates transcription of Endoglin   
 To determine whether PRH regulates Endoglin expression in normal prostate cells 
and prostate cancer cells we used quantitative RT-PCR to measure Endoglin mRNA levels in 
PNT2-C2 cells and PC3 cells. We infected the cells with an empty adenovirus or with an 
adenovirus that expresses Myc-tagged PRH (Ad PRH) (28) . In both PNT2-C2 cells and PC3 
cells infection with Ad PRH brings about a significant increase in Endoglin mRNA levels 
(Fig.3A). Endoglin protein levels are also increased in cells over-expressing PRH (Fig.3B). 
Conversely, Endoglin protein levels are significantly reduced in PNT2-C2 cells in which 
PRH has been knocked down using shRNA (Fig.3C). Interestingly, Endoglin protein levels 
are significantly reduced in both prostate cancer cell lines compared to PNT2-C2 cells 
(Fig.S2A and S2B). The Endoglin promoter contains several putative PRH binding sites both 
proximal and distal to the transcription start site. To determine whether PRH binds to the 
Endoglin promoter we performed chromatin immunoprecipitation (ChIP) experiments. 
PNT2-C2 cells were infected with Ad PRH and chromatin from these cells was isolated and 
sheared by sonication. ChIP using a Myc antibody was then used to isolate DNA fragments 
bound to Myc-PRH. PCR with a primer pair specific for Endoglin promoter sequences from -
1042 to -551 relative to the first exon (Fig.3D) indicates that PRH binds at or near this region 
(P1 in Fig.3D). This region contains three putative PRH binding sequences as defined by the 
presence of 5’TAAT3’ motifs. Promoter sequences flanking a previously characterised 
enhancer (29, 30) located 8kb upstream of first exon also contain multiple putative PRH 
binding sites. Primer pairs specific for promoter sequences from -7352 to -6914  and -8857 to 
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-8398 (which contain 1 and 6 putative PRH binding sites respectively) show that PRH can 
also bind in these regions in PNT2-C2 cells (P3 and P4 in Fig.3D). This binding is unlikely to 
be an artefact of PRH over-expression since a primer pair specific for promoter sequences 
from -1547 to -1353 that lacks putative PRH sites fails to produce a product (P2 in Fig.3D). 
Moreover the PRM2 gene is highly expressed in tumour cells and primer pairs for this locus 
were used as a control to show that there is little non-specific enrichment of sequences from 
elsewhere in the genome using these conditions.  
Reporter assays using a series of Endoglin promoter fragments cloned upstream of the 
luciferase gene confirm that sequences between -851 and -400 are responsive to PRH over-
expression (Fig.S3B). However, unexpectedly, PRH over-expression represses the activity of 
Endoglin reporter constructs that contain this PRH-responsive region. This suggests that 
activation of the endogenous Endoglin promoter by PRH is complex and that it might require 
the presence of chromatin/chromatin associated factors or that activation is mediated by the 
promoter distal PRH binding sites identified above using ChIP.  
 
Endoglin over-expression inhibits the increased migration of PRH knockdown cells 
The data shown above suggest that PRH inhibits cell migration by the direct 
transcriptional regulation of Endoglin. To investigate this in more detail we over-expressed 
Endoglin in prostate cells (Fig.S4A). As expected, over-expression of Endoglin inhibits 
migration (Fig.S4B) and invasion by PC3 cells and DU145 cells (Fig.S4C). As mentioned 
earlier, PNT2-C2 PRH knockdown cells show increased cell migration. Over-expression of 
Endoglin in PNT2-C2 PRH knockdown cells completely abrogates the increased migration of 
these cells in wound closure assays (Fig.4A). Moreover, although over-expression of 
Endoglin has little or no effect on chemotaxis by PNT2-C2 cells (Fig.4B), Endoglin over-
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expression completely abolishes the increased chemotaxis shown by PNT2-C2 PRH 
knockdown cells (Fig.4B, lanes 3 and 4). We conclude that the effects of Endoglin on cell 
migration are downstream from PRH. This suggests that PRH does indeed inhibit cell 
migration through the direct regulation of Endoglin expression. 
To investigate whether TGF signalling is involved in the control of cell migration by 
PRH, we made use of a specific inhibitor that targets TGF superfamily type I activin 
receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. The inhibition of TGF 
signalling abrogates the negative effects of PRH over-expression on the migration of DU145 
cells (Fig.4C). Furthermore, inhibition of TGF signalling also abrogates the negative effects 
of Endoglin over-expression on the migration of these cells (Fig.4C). As expected, the levels 
of phosphorylated Smad3, a downstream target for TGF-β-induced phosphorylation, are 
reduced in the treated cells (Fig4D). This indicates that both PRH and Endoglin inhibit 
prostate cell migration through the down-regulation of TGF signalling. 
 
 
PRH inhibits the migration of normal breast epithelial cells and breast cancer cells 
 Since PRH is known to be aberrantly localised in breast cancer cells (9), we next set 
out to determine whether this protein also controls the migration of normal breast epithelial 
cells and breast cancer cells. We knocked down PRH in normal immortalised breast epithelial 
MCF 10A cells using a lentivirus expressing an IPTG-inducible shRNA against PRH 
(Fig.5A). Interestingly three independent PRH knockdown cell lines show a significant 
increase in chemotaxis compared to controls (Fig.5B). To investigate the effects of PRH on 
breast cancer cell migration and cell invasion we made use of two well characterised breast 
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cancer cell lines: MCF-7 cells, an estrogen receptor (ER) positive breast adenocarcinoma cell 
line, and MDA-MB-231 cells, a hormone-independent breast adenocarcinoma cell line. We 
infected these cells with Ad PRH or empty adenovirus and examined the effects on cell 
migration in scratch wound assays. In both cases cells infected with Ad PRH show a decrease 
in wound closure (Fig.S5A). In chemotaxis experiments infection with Ad PRH results in a 
significant reduction in cell migration in both cell lines (Fig.5C). To confirm that this 
reduction in cell migration is not due to adenoviral infection we also examined the migration 
of MCF-7 PRH knockdown cells (Fig.5A, left). Three independent MCF-7 cell lines 
transduced with lentiviruses expressing PRH shRNA exhibit a significant increase in wound 
closure (Fig.5D). We next transiently transfected MDA-MB-231 cells with a vector 
expressing GFP or with GFP and PRH expression vectors and performed invasion assays. As 
in PC3 cells and DU145 cells, over-expression of PRH dramatically reduces the ability of 
MDA-MB-231 cells to invade Matrigel (Fig.5E).   
 Similar to the results seen in prostate cells, Endoglin protein levels are higher in 
normal breast MCF 10A cells than in either MCF-7 cells or MDA-MB-231 cells (Fig.S5B 
and S5C). To examine whether the ability of PRH to influence the migration of MCF 10A 
cells and breast cancer cells also involves the regulation of Endoglin we measured Endoglin 
mRNA levels in MCF-7 and MCF 10A cells over-expressing PRH. In both cases PRH over-
expression results in a significant increase in Endoglin mRNA (Fig.5F). Moreover, Endoglin 
protein levels are decreased in PRH knockdown MCF 10A cells (Fig.5G). The effects of PRH 
on Endoglin mRNA and protein expression appear to be direct since ChIP of Myc-tagged 
PRH pulls down Endoglin promoter sequences in both MCF-7 and MCF 10A cells 
(Fig.S5D). These data suggest that PRH inhibits the migration of normal breast cells and 
breast cancer cells via transcriptional regulation of Endoglin expression.  
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DISCUSSION 
 The ability of PRH/HHex to control cell proliferation and cell differentiation in 
multiple cell types is well documented.  PRH can control cell proliferation via the post-
transcriptional regulation of cyclin D mRNA transport (2). In addition, our previous work has 
shown that in leukaemic cells, PRH directly represses multiple genes that encode proteins 
involved in VEGF signalling including Vegfa and Vegfr-1 (31). In these cells VEGF acts as 
an autocrine growth factor and the transcriptional regulation of these VEGF signalling genes 
by PRH controls cell survival. The extent to which these modes of cell survival control 
operate in other cell types is not known, although in breast cancer MCF-7 cells, PRH 
regulates the transcription of Vegf receptor genes and a PRH knockdown increases cell 
growth (31).  In endothelial cells PRH over-expression also controls VEGF signalling genes 
and alters cell migration and invasion (24). In breast and thyroid cancer cells PRH subcellular 
localisation is altered resulting in cytoplasmic and nucleolar accumulation of PRH (9, 10). 
However, the ability of PRH to regulate other aspects of cancer cell behaviour relevant to 
tumourigenesis, including cell motility and cell invasion, has not been investigated.  
 Here we have shown that PRH knockdown increases the motility of immortalised 
prostate and breast epithelial cells and increases chemotaxis by these cells. Conversely, PRH 
over-expression decreases cell migration by prostate and breast cancer cells and inhibits the 
ability of these cells to invade a Matrigel layer. Moreover, PRH over-expression decreases 
the ability of prostate cancer cells to travel though a layer of endothelial cells in extravasation 
assays. These findings suggest that the aberrant localisation of PRH seen in breast cancer 
cells and thyroid cancer cells could contribute to their increased migration and cell invasion 
as well as having effects on cell proliferation. Moreover, these results show that PRH activity 
is important in the control of these aspects of cell behaviour in normal epithelial cells and 
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they suggest that PRH may also be aberrantly localised or otherwise misregulated in prostate 
cancer cells.  
 Knockout of PRH in embryoid bodies results in down-regulation of Endoglin mRNA 
(32) and PRH over-expression has been shown to up-regulate Endoglin mRNA and protein 
levels in endothelial cells (24). We have shown that PRH associates directly with the 
Endoglin promoter and up-regulates transcription of Endoglin in normal prostate and breast 
epithelial cells and prostate and breast cancer cell lines. PRH binds to DNA sequences within 
the Endoglin proximal promoter located around 500bp upstream of the transcription start 
point and upstream of a number of important transcription factor binding sites including sites 
for regulation by Sp1, HIF-1, Smad proteins, KLF6 and ETS family members  (30, 33-35). 
PRH also binds to sequences in the distal promoter near a previously characterised Enhancer 
(29, 30) around 8kb upstream of the transcription start point. These regions both contain 
multiple copies of the core PRH binding site 5‘TAAT’3. Other PRH target genes including 
Goosecoid, VegfR1 and Vegfa also contain arrays of PRH core binding sites and at these 
promoters PRH also binds over extensive regions (36, 37). This suggests that PRH oligomers 
bind to these promoters in a similar manner in order to control promoter architecture. 
However, at other promoters PRH binds in conjunction with other transcription factors and in 
these cases extensive direct contacts between PRH and the DNA may not be required (1). 
Surprisingly, although the promoter proximal binding sites in the Endoglin promoter confer 
responsiveness to PRH over-expression in luciferase assays, PRH appears to repress Endoglin 
transcription when bound at these sites. Presumably, the promoter distal PRH binding sites 
are responsible for Endoglin transcription activation by PRH. Alternatively, the presence of 
chromatin/chromatin associated factors  may be important for activation of the Endoglin 
promoter by PRH just as they are for repression by PRH at the Vegfr-1 promoter (31). 
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Further experiments will be required to determine the mechanisms that PRH uses in order to 
activate transcription at this promoter. 
 Importantly, the increased cell migration shown by PRH knockdown cells is 
completely abolished by Endoglin over-expression. We conclude that in both breast and 
prostate cells PRH regulates Endoglin expression and that the effects of PRH on cell 
migration are in part at least through the control of this target gene. Endoglin has been shown 
to inhibit cell migration, cell invasion and tumour growth by prostate cancer cells and cell 
migration and invasion of breast cancer cells (18, 23). However, it has been reported that 
Endoglin expression is higher in metastatic cancer epithelial cells and prostatic intraepithelial 
neoplasia compared to benign or normal prostate cells (38). Moreover, in highly metastatic 
breast cancer cells increased Endoglin expression is associated with invasion and metastasis 
(39). It would seem likely that the effects of Endoglin over-expression may depend on the 
cell type and/or the over-expression level as well as interplay between the tumour and the 
stroma and inputs from multiple signalling pathways. However, we have observed decreased 
Endoglin expression in prostate tumour cells and breast tumour cells relative to immortalised 
cells. Henry et al also reported decreased Endoglin expression in most breast tumour cell 
lines relative to immortalised cells and detected Endoglin expression in only a minority of 
primary tumours (23). We expect that the regulation of Endoglin by PRH is disrupted in 
breast cancer cells. Further experiments will be required to determine whether PRH activity 
in prostate cancer cells is disrupted by changes in PRH localisation as has been observed in 
breast cancer cells (9) or by some other mechanism. However, it would seem likely that in 
both of these cancer types and in other cancer cells in which PRH is aberrantly localised, the 
loss of PRH activity may contribute to increased cell invasion, increased cancer metastasis 
and ultimately, decreased patient survival in part at least through a decrease in Endoglin 
expression. Loss of PRH activity would also be expected to derepress VEGF signalling genes 
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resulting in increased cell survival and/or increased neoangiogenesis. This combination of 
outcomes arising from the loss of PRH activity suggests that this protein plays a critical role 
in tumourigenesis.  
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MATERIALS AND METHODS 
Expression vectors and reporters 
 pMUG1-Myc-PRH expresses human PRH tagged with the Myc9E10 epitope (3). 
pMUG1-Myc-PRH N187A and pMUG1-Myc-PRH F32E express mutated PRH proteins that 
fail to bind DNA and TLE respectively (3). The plasmids shRNAPRH49 and shRNAPRH51 
and control shRNA plasmid were obtained from Origene. The Endoglin expression vector 
pcDNA3.1-Endoglin (long isoform) was a gift from Professor Clare Isacke. The recombinant 
adenoviral construct expressing Myc-PRH has been described previously (28). pCD105(-
2450/+350), pCD105(-851/+350) and pCD105(-400/+350) containing Endoglin promoter 
sequences cloned upstream of the firefly luciferase gene were a gift from Professor Carmelo 
Bernabeu (34, 35). pRL-CMV expressing Renilla luciferase was purchased from Promega. 
Lentiviral constructs expressing IPTG-inducible PRH shRNA or a control shRNA were 
obtained from Sigma. 
 
Cell culture 
 PNT2-C2, PC3, DU145, MCF-7 and MDA-MB-231 cells were cultured in RPMI-
1640 supplemented with 10% FBS, 2mM L-glutamine and 1% Penicillin/Streptomycin. 
MCF 10A cells were cultured in DMEM:F12 (Sigma) supplemented with 5% Horse Serum 
Heat-Inactivated (Sigma), 20ng/ml EGF (Peprotech) 0.5ug/ml Hydrocortisone (Sigma), 
100ng/ml Cholera toxin (Sigma), 10g/ml Insulin (Sigma) and 1% Penicillin/Streptomycin. 
Human umbilical vein endothelial cells were cultured in DMEM:F12 supplemented with 
5ng/ml EGF (Peprotech), 10ng/ml bFGF, 20g/ml Heparin, 1g/ml Hydrocortisone, 
250ng/ml Insulin, 1% Penicillin/Streptomycin and 2% FCS. All cells were maintained in a 
humidified atmosphere at 37°C and 5% CO2.  
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Transient transfection 
 PNT2-C2 cells, PC3 cells and DU145 cells were transfected using TransIT® (Mirus). 
MCF-7 cells and MDA-MB-231 cells were transfected using Lipofectamine 2000 
(Invitrogen). PC3 cells were transfected for luciferase assays using electroporation (250 V, 
975 μF).  
 
Luciferase assays 
PC3 cells were transiently transfected with reporter plasmids and either pMUG1-
Myc-PRH or empty pMUG1 vector. After 24 hours at 37°C and 5% CO2 the cells were lysed 
and assayed for luciferase activity using a dual luciferase assay system (Promega) and a 
Berthold Technologies luminometer. Renilla luciferase activity was used as an internal 
control for transfection efficiency. 
 
PRH knockdown 
 Knockdown of PRH in PNT2-C2 cells was performed as described previously (31). 
Knockdown of PRH in MCF-7 and MCF 10A cells was performed using an IPTG-inducible 
PRH shRNA lentiviral construct (Sigma). Cells were infected with the PRH shRNA lentiviral 
construct or a control scrambled shRNA lentivirus and after 48 hours transduced cells were 
selected using puromycin. Stably transduced cell lines were grown in the presence of 1mM 
IPTG for 7 days to induce shRNA expression.  
 
Cell migration assays 
 Cell monolayers on microscope coverslips were produced plating cells infected with 
Ad PRH or empty adenovirus (MOI 50) and incubating the cells for 24 hours at 37°C and 5% 
CO2. After the addition of 1M hydroxyurea (Sigma) to inhibit cell division a wound was 
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created using a P1000 pipette tip. Pictures were taken using a Leica DMIRBE microscope 
with Hamamatsu CCD camera or a AMG EVOS XL CORE AMEX 1200 and the width and 
area of the wound was quantified using ImageJ software (40).  
 Chemotaxis assays were performed by seeding cells onto 8µm Boyden chambers 
(Greiner Bio-One) in RPMI with 2% FBS. The chambers were placed into 24 well plates 
containing RPMI with 10% FBS to create a serum gradient. In some experiments cells, were 
seeded in the presence of 3M ALK 4/5/7 kinase inhibitor SB-431542 (Sigma) or DMSO. At 
the time points indicated the cells were fixed with 4% paraformaldehyde (Fisher) and stained 
with 2µg/ml bisbenzimide (Sigma). Cells on the top and bottom of the membrane were 
counted using a Leica Q550 inverted epifluorescence microcope or Zeiss axioplan 2.  
 Invasion assays were performed as above except that 50% Matrigel (BD Biosciences) 
was added to the Boyden chambers and left at 37°C for 1 hour to solidify prior to seeding the 
cells. Extravasation assays were performed as described by Ma and Wang (41) except that 
PC3 cells were dissociated using Cell Dissociation Solution (Sigma) prior to seeding on the 
HUVEC layer. 
 
Quantitative reverse transcriptase-mediated PCR (RT-qPCR) 
 RNA was purified 48 hours post-infection as described previously (31, 42). 
Quantitative PCR was performed in triplicate with Endoglin and Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) primers (shown below). Data were analysed using Rotorgene 6 
software (Corbett Research; Rotorgene RG-3000) with GAPDH mRNA as an internal 
control. 
Endoglin 5’ GCCGTGCTGGGCATCACCTT 3’ 5’ CGCTTGCTGGGGGAACCTGG 3’, 
annealing at 60°C.  
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GAPDH 5’ TGATGACATCAAGAAGGTGGTGAAG 3’ 5’ TCCTTGGAGGCCATGT 
GGGCCAT 3’, annealing at 55°C. 
 
Western blotting  
 Whole cell extracts were prepared using TES buffer (1% SDS, 2mM EDTA, 20mM 
Tris-HCl pH 7.4) as described previously (27). A rabbit polyclonal antibody was used to 
detect Endoglin (Abcam). PRH antibodies have been described previously (3, 42). Lamin 
A/C and Tubulin antibodies were from Santa-Cruz. Densitometry was performed using 
Quantity One 4.6 software (BioRad). Phosphorylated Smad3 (Ser423/425) was detected 
using a rabbit monoclonal antibody (Cell Signaling Technology).  
 
Chromatin immunoprecipitation 
 Cells were infected with Ad PRH or control virus (MOI 50) and incubated for 24 
hours at 37°C and 5% CO2 before fixation in 1% formaldehyde for 8 minutes at 21°C. 
Glycine was added to a final concentration of 125mM, then the cells were pelleted by 
microcentrifugation at 4°C, resuspended in 130µl lysis buffer (50mM Tris-Cl pH 8.0, 10mM 
EDTA, 1% SDS, 1mM PMSF and protease inhibitor cocktail (Roche)) and sonicated in a 
Biorupter (Diagenode) for 20 minutes on high power at 4°C. Dynabeads® protein A 
magnetic beads (Invitrogen) were incubated with normal mouse IgG (Santa Cruz) or 
Myc9B11 (Cell Signalling Technology) in RIPA buffer (10mM Tris-Cl pH 8.0, 140mM 
NaCl, 1% v/v Triton X-100, 1mM EDTA, 0.5mM EGTA, 0.1% w/v SDS, 0.1% sodium 
deoxycholate) for 2 hours at 4°C on a rotary wheel. Chromatin lysates were incubated with 
antibody:bead complexes overnight at 4°C on a rotary wheel. Beads were washed x3 with 
1ml RIPA buffer, 1ml RIPA containing 500mM NaCl, 1ml RIPA containing 0.5% NP-40 and 
twice with 1 ml TE buffer (10mM Tris-Cl pH 8.0, 1mM EDTA pH 8.0) and resuspended in 
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elution buffer (20mM Tris-Cl pH 7.5, 50mM NaCl, 5mM EDTA, 1% SDS). After digestion 
with proteinase K for 2 hours at 68°C DNA was obtained by phenol chloroform isoamyl 
alcohol extraction and precipitated prior to resuspension in TE. Binding was analysed by 
PCR (95°C for 1 min, 60°C for 1 min, 72°C for 1 min) using the following Endoglin primer 
pairs: P1 5’ CAGGAAGGCATCGTGCCCCA 3’ 5’ TCACCGACAAAACACAGCTCCA 
3’, P2: 5’CTCTGCCAGCGTCCTTCTGCTC 3’ 5’ AGGGTGCCAGACTAAGC 
AAAGCAAC 3’, P3 5' GGGTTGCCATGGTGGGAATATA 3’ 5’ TATGGGTGTT 
GGGGGCATTC 3’, P4 5’ AGCTAATAGCCCGTGTGCAA 3’ 5’ AGGGGGAGAG 
TGGTCCTAGA 3’. The prm2 gene was used as a negative control: prm2 primers 
5’ TGTACAGGCAGCAGTTGCATGG 3’ 5’ CTCCTTCGAGAGCAGTGTCTGC 3’ 
(annealing temperature 62°C, 33 cycles). 
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FIGURE LEGENDS 
Figure 1.  PRH regulates cell motility. (A) PNT2-C2 cells were transfected with plasmids 
expressing PRH shRNAs or a control shRNA and grown for ten days in puromycin selection. 
Western blotting of day 10 whole cell extracts was performed using a monoclonal antibody 
that recognises PRH. The two bands detected represent hyper- and hypo-phosporylated PRH 
(42). Antibodies that recognise Tubulin confirm equal loading. (B) PRH protein levels in 
three independent experiments after 10 days in selection were quantified relative to Tubulin. 
The graph shows the average PRH level. Mean and standard deviation (M+SD), n=3. ** 
indicates P<0.01. (C) After 10 days in selection control cells (top) and PRH knockdown 
PNT2-C2 cells (bottom) were used to produce confluent monolayers. The monolayers were 
wounded with a pipette tip and imaged at 0, 6 and 18 hours. Representative images from n=4. 
(D) Wound width was measured at 5 locations and is plotted as percentage wound width 
remaining. M+SD, n=4. (E) Transwell chemotaxis assays using control cells (open bars) and 
PRH knockdown PNT2-C2 cells (shaded bars). The graph shows the percentage of cells 
migrated in ten fields of view at the time points shown. M+SD. n=2. *** indicates P<0.001. 
 
Figure 2.  PRH over-expression inhibits prostate cell migration and cancer cell invasion. 
(A) Transwell chemotaxis assays were performed using cells transiently transfected with a 
vector expressing GFP (open bars) or vectors expressing GFP and PRH (shaded bars). The 
graph shows the percentage of migrated cells in ten fields of view after 24 hours. M+SD. 
n=2. ** indicates P<0.01. (B) DU145 cells were transiently transfected with a vector 
expressing GFP or vectors expressing GFP and either wild type PRH, PRH N187A or PRH 
F32E. 24 hours post-transfection the cells were plated in transwell inserts and after a further 
24 hours the number of migrated green cells was determined by counting cells in ten fields of 
 22 
view. M+SD. n=5. * indicates P<0.05.  (C) Myc-PRH protein levels in whole cell extracts 
prepared from the cells in part (B) were determined using western blotting. Lamin A/C was 
used as a loading control. (D) Transwell invasion assays were performed using cells 
transiently transfected with a vector expressing GFP (open bars) or vectors expressing GFP 
and PRH (shaded bars). The graph shows the percentage of invaded cells in ten fields of view 
after 24 hours. M+SD. n=2. *** indicates P<0.001. (E) In vitro extravasation assays were 
performed using HUVECs grown as a monolayer on Matrigel in Boyden chambers. PC3 cells 
were transiently transfected with a vector expressing GFP (open bars) or vectors expressing 
GFP and PRH (shaded bars) prior to seeding on the HUVEC layer. The graph shows the 
number of invaded cells in ten fields of view after 12 hours. M+SD. n=3. * indicates P<0.05.  
 
Figure 3.  PRH directly activates Endoglin expression. (A) Endoglin mRNA levels in 
PNT2-C2 cells and PC3 cells 48 hours post-infection with an empty adenoviral vector (open 
bars) or an adenoviral vector expressing PRH (shaded bars). mRNA levels were measured by 
RT-qPCR and compared to Gapdh mRNA levels. M+SD, n=3. *indicates P<0.05. (B) Top- 
Endoglin protein levels in whole cell extracts prepared from the cells described in (A) were 
determined using western blotting. Antibodies that recognise Tubulin confirm equal loading. 
Bottom- The graph shows Endoglin protein levels in the cells described above determined 
using densitometry. M+SD, n=3. * indicates P<0.01. (C) Top- Endoglin protein levels in 
whole cell extracts prepared from control PNT2-C2 cells (1) and PRH knockdown PNT2-C2 
cells (2) at day 10 in selection were determined using western blotting. Antibodies that 
recognise Lamin A/C confirm equal loading. Bottom- The graph shows Endoglin protein 
levels in PRH knockdown PNT2-C2 cells compared to control PNT2-C2 cells. M+SD, n=4. 
** indicates P<0.01. (D) Upper panel- a cartoon of the Endoglin promoter region, showing 
the transcription start point (bent arrow) and primers used for ChIP. Lower panels- Myc-PRH 
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was expressed in PNT2-C2 cells using Ad PRH. ChIP was then performed as described in the 
text. Each panel shows the result of PCR with primer pairs P1-P4 and input chromatin (1), 
chromatin precipitated with IgG (2), Myc antibody (3), or a no template control (4). 
 
Figure 4. Endoglin over-expression abrogates the effects of a PRH knockdown on cell 
migration. (A) PNT2-C2 cells were transfected with plasmids expressing PRH shRNAs or a 
control shRNA and grown for ten days in puromycin selection. The cells were then 
transiently transfected with an Endoglin expression vector or a control empty vector and 
plated out to produce confluent monolayers as in Figure 1. The monolayers were wounded 
with a pipette tip and imaged at 0, 6, 18 and 24 hours. After imaging wound width was 
measured at 5 locations and is plotted as percentage wound width remaining. M+SD, n=3. 
(B) Control PNT2-C2 cells (open bars) and PRH knockdown PNT2-C2 cells (shaded bars) 
were grown for 10 days in puromycin selection and then transiently transfected with an 
Endoglin expression vector or empty vector as in (A). 24 hours post-transfection transwell 
chemotaxis assays were performed as in Figure 1. The graph shows the percentage of cells 
migrated in ten fields of view after 24 h. M+SD, n=2.  ** indicates P<0.01. (C) DU145 cells 
were transiently transfected with vectors expressing GFP alone (1 and 2), GFP and PRH (3 
and 4), or GFP and Endoglin (5 and 6). After 24 hours transwell chemotaxis assays were 
performed as above but in the absence (-) or presence (+) of 3µM SB-431542. The graph 
shows the percentage of cells migrated in ten fields of view after 24 hours. M+SD, n=2.  * 
indicates P<0.05. (D) DU145 cells were treated with 3µM SB-431542 for 24 hours or left 
untreated. Western blotting was then performed using antibodies that recognise 
phosphorylated SMAD3 and antibodies that recognise Lamin A/C as a loading control. 
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Figure 5.  PRH regulates breast cancer cell migration and invasion. (A) MCF 10A cells 
and MCF-7 cells were transduced using a control lentivirus that activates RISC and the RNAi 
pathway but does not target any known gene (1) or a lentivirus expressing PRH shRNA (2). 
shRNA expression was then induced using IPTG for 7 days. Western blotting of whole cell 
extracts was performed using a monoclonal antibody that recognises PRH and antibodies that 
recognise Tubulin or Lamin A/C. (B) Transwell chemotaxis assays were performed using 
control MCF 10A cells (open bars) and PRH knockdown MCF 10A cells (shaded bars). The 
graph shows the percentage of cells migrated in five fields of view after 24 hours. M+SEM, 
n=4.  * indicates P<0.05. (C) MCF-7 cells and MDA-MB-231 cells were infected with empty 
Ad empty (open bars) or Ad PRH (filled bars). 24 hours post-infection transwell chemotaxis 
assays were performed as above. The graph shows the percentage of cells migrated in five 
fields of view after 24 hours. M+SEM, n=3.  ** indicates P<0.01. (D) PRH knockdown 
MCF-7 cell lines and control cells were plated to produce confluent monolayers and then 
wounded as in Figure 1. After imaging wound area was measured in six fields of view in 
three independent clones and is plotted as percentage wound area remaining. M+SD, n=3.  
*** indicates P<0.001. (E) Transwell invasion assays were performed using MDA-MB-231 
cells transiently transfected with a vector expressing GFP (open bar) or vectors expressing 
GFP and PRH (shaded bar). The graph shows the percentage of invaded cells after 24 hours. 
M+SEM, n=3.  * indicates P<0.05. (F) Endoglin mRNA levels in MCF 10A cells and MCF-7 
cells 48 hours post-infection with Ad empty (open bar) or Ad PRH (shaded bar). Endoglin 
mRNA levels were measured by RT-qPCR and compared to Gapdh mRNA levels. M+SD. 
n=4. * indicates P<0.05. (G) Western blotting for Endoglin in whole cell extracts prepared 
from control MCF 10A cells (1) or MCF 10A PRH knockdown cells (2). Tubulin was used as 
a loading control. 
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